News

The National Institute for Health and Care Excellence23h
Deal agreed for continued access to life-changing treatment for rare inherited disease
NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.
The National Institute for Health and Care Excellence1d
Health inequalities - an update to NICE’s methods for health technology evaluation
This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...
National Institute for Health and Care Excellence3d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
National Institute for Health and Care Excellence3d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence3d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations ...
National Institute for Health and Care Excellence3d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
Erdafitinib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic urothelial cancer with susceptible FGFR3 genetic alterations in adults after at ...
National Institute for Health and Care Excellence3d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
The National Institute for Health and Care Excellence5d
Technology for children and young people with chronic tic disorders and Tourette syndrome recommended
A digital therapy that could reduce the severity of the symptoms of chronic tic disorders and Tourette syndrome has been conditionally recommended for NHS use. These cookies remember information that ...
National Institute for Health and Care Excellence7d
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management
You can now comment on this draft scope. The scope defines what the guideline will (and will not) cover. NICE is transforming to deliver more timely, relevant and impactful guidance while maintaining ...
National Institute for Health and Care Excellence7d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
National Institute for Health and Care Excellence7d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...